Value-Based Care, Quality Payment Program, Research Funding, Telomeres, and the ROCKET Trial
This week’s BioBlog focuses on the the continued push toward Value-Based Care even with expected changes to the ACA, physician readiness to comply with the Quality Payment Program, cancer research funding, telomere research, and cancer treatment trial complications.
PRWeb reports that they expect Trump to eliminate the Affordable Care Act via a budget reconciliation early in his term, while still keeping some elements of it including the trend toward value-based care.
In this article, The ASCO Post discusses the implementation of the Quality Payment Program and what adjustments physicians need to make to meet the new requirements of this program.
The University of Queensland in Australia was awarded a $2.3 million grant to study and track how cancer cells grow and react to various cancer treatments.
Two University of Pittsburgh Medical Center labs are currently researching telomeres and the role they play in the spread of cancer.
CNN Reports that the ROCKET immunotherapy trial has been halted again after two more participants experienced cerebral edema and passed away. Earlier this year the trial was temporarily stopped when three additional participants died.